Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track RPRX with free AI briefings, catalyst countdowns, and dilution alerts.

RPRX · Royalty Pharma plc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$894.9M Cash on Hand
CF+ Cash Runway
Follow RPRX by email Get an email when RPRX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about RPRX, unsubscribe in one click. Privacy

📣 What RPRX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus

Also used in these trials (approved or third-party drugs, not RPRX's own candidates): Valacyclovir.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

RPRX holds $894.9M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when RPRX files for a raise →

👥 Who Owns RPRX

Insiders 1.6% Other 5%+ holders 6.2% Institutions (1038 holders) 88.6% Public and other holders 3.6%
HolderTypeShares% of sharesAs of
Capital International Investors Institution (13G, 5%+) 37,772,419 9.73% 2026-03-31
R & H Trust Co. (Guernsey) Limited 5%+ holder (13D) 24,223,082 6.24% 2025-11-06
Pablo G. Legorreta
CEO, Chairman of the Board, Director · +809,715 options
Insider 4,954,404 1.28% 2026-11-04
Terrance P. Coyne
EVP & CFO · +1.83M options
Insider 307,512 0.08% 2026-11-04
Christopher Hite
EVP & Chairman, Partnering
Insider 300,723 0.08% 2026-11-04
Gregory Norden
Director
Insider 196,348 0.05% 2026-06-05
Marshall Urist
EVP, Research & Investments · +473,824 options
Insider 174,361 0.04% 2026-11-04
Bonnie L Bassler
Director
Insider 79,823 0.02% 2026-09-30
Ted W Love
Director
Insider 58,393 0.02% 2026-06-05
Catherine M. Engelbert
Director
Insider 55,673 0.01% 2026-06-05
David C Hodgson
Director
Insider 37,873 0.01% 2026-06-05
Vlad Coric
Director
Insider 15,343 0.00% 2026-06-05

Share count 388,132,400 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full RPRX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for RPRX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.